DDI-DrugBank.d728.s0 >> No specific cytochrome P450-based drug interaction studies have been conducted.
DDI-DrugBank.d728.s1 >> No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks. >> 48-55,72-75
DDI-DrugBank.d728.s2 >> Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. >> 13-16,104-111
DDI-DrugBank.d728.s3 >> Since platinum containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds;
DDI-DrugBank.d728.s4 >> although, this has not been specifically studied.
